The incidence of oesophageal adenocarcinoma, which has a 5-year survival rate of 15%, has rapidly increased in the last years. The risk factors for oesophageal adenocarcinoma include chronic reflux, male gender, obesity and Barrett’s oesophagus, a metaplastic change of the oesophageal squamous epidermal cells which are replaced by columnar cells. There is a need to understand the underlying mechanism of oesophageal adenocarcinoma development and find potential biomarkers. MALDI (Singhal et al. 2013) and spectroscopy (Dave et al. Eur J Gastroenterol Hepatol) studies report changes in the lipid profiles of Barrett’s oesophagus and/or adenocarcinoma tissue compared to healthy squamous epithelium. Interestingly, cholesterol lowering drugs of the statin family have been reported to attenuate growth and malignant potential of oesophageal adenocarcinoma cells (Sadaria et al. 2011), and a more recent study report statin use as protective against Barrett’s oesophagus and adenocarcinoma (Nguyen et al. 2014, 2015). To determine if lipid composition changes during the development of oesophageal adenocarcinoma, we conducted an untargeted mass spectrometry-based lipidomics experiment in five cell lines representing progression from Barrett’s oesophagus, dysplasia to oesophageal adenocarcinoma. This poster will report the initial results.